JCEM：青少年胰岛素增敏治疗可预防刚出生雄激素过多的表型

EE-CA和PioFluMet化疗中会和化疗后CRP、CIMT、内脏油脂和MSI改变

口服雌孕激素是魔女甲状腺激素极少的标准化疗，即使当这些妈妈没有哺乳的风险。为了比较口服避孕药与血糖增敏化疗插手非厌食症青少年，在化疗中会和化疗后对甲状腺激素极少的负面影响，来自巴萨罗那的大学Sant Joan de Deu医院内增生科的Lourdes Ibanez教授及其团队进行了一项科学研究，该科学研究发现青少年血糖增敏化疗插手确实卫生保健成年部份甲状腺激素极少表HG。该科学研究结果在线发表在2012年4年初1日的美国《临床内增生代谢物时尚杂志》（The journal of clinical endocrinology & metabolism）上。该科学研究是一项随机非盲试验，受试者是很较差血糖胆固醇和甲状腺激素极少的非厌食症魔女，且没有哺乳的风险（34举例；总人数16岁；体重加权：23kg/m2）。科学研究比较炔雌醇甲醛环丙雌二醇（EE-CA）与小剂量磺酸列酮（7.5mg/d）、氟他米特（62.5mg/d）和二甲双苯甲酸（850mg/d）建立联系（PioFluMet）化疗18个年初的。化疗后随访6年初。精确测量甲状腺激素极少（蚯蚓症、痤疮分数和血浆睾酮），冲动后血糖，循环C底物蛋白，颈动脉内膜最上层厚度，身体组成（吸**确测量法），腹部油脂分区（医学影像全像）和年初经周期。该科学研究分析表明，EE-CA和PioFluMet同样缓解甲状腺激素极少，但有差异，以致负面影响其他结果。化疗后6个年初，PioFluMet化疗的妈妈比EE-CA化疗的妈妈有更较差的冲动后血糖，更较差的C底物蛋白水平和更薄的内膜最上层，并且他们的内脏油脂较少，具有更好的瘦体重，以及更确实比较简单的年初经周期。该科学研究发现，在非厌食症的甲状腺激素极少的青少年，PioFluMet化疗中会和化疗后的比口服避孕药的好。插手依靠青少年甲状腺激素极少的减少负面影响化疗后的表HG。在青少年，PioFluMet相近的插手确实卫生保健成年部份甲状腺激素极少的表HG，包括厌食症和生育能力较差下。与很较差血压关的的扩展阅读：

Diabetes Care：很较差血压与心衰很较差血压心脏中枢神经系统活性减少关的Diabetes Care：lixisenatide有效率改善二甲双苯甲酸控制不佳的2HG很较差血压人群的血糖2013 NIH 哺乳期很较差血压(GDM)诊断声明JAMA：褪黑激素增生减少增加IIHG很较差血压风险DIABETES CARE：空腹血糖乳癌哺乳很较差血压添新证Eur J Endocrinol: 1HG很较差血压很较差血压HbA1c水平过很较差能单独所致精神病更多信息请点击：有关很较差血压更多资讯

Oral Contraception vs Insulin Sensitization for 18 Months in Nonobese Adolescents With Androgen Excess: Posttreatment Differences in C-Reactive Protein, Intima-Media Thickness, Visceral Adiposity, Insulin Sensitivity, and Menstrual Regularity BackgroundAn oral estro-progestagen is the standard medication given to adolescent girls with androgen excess, even when those girls are not at risk of pregnancy. AimThe aim of this study was to compare on-treatment and post-treatment effects of intervention with an oral contraceptive vs an insulin-sensitizing treatment for androgen excess in nonobese adolescents. DesignThis was a randomized, open-label trial. Study PopulationSubjects were nonobese adolescent girls with hyperinsulinemic androgen excess and without risk of pregnancy (mean age, 16 years; body mass index, 23 kg/m2; n = 34). InterventionsThe effects of treatment with ethinylestradiol-cyproteroneacetate (EE-CA) vs a low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet) for 18 months were studied. Posttreatment follow-up was for 6 months. Main Outcome MeasuresAndrogen excess (hirsutism and acne scores and serum testosterone), glucose-stimulated insulinemia, circulating C-reactive protein, carotid intima media thickness, body composition (absorptiometry), abdominal fat partitioning (magnetic resonance imaging), and menstrual regularity were measured. ResultsEE-CA and PioFluMet attenuated androgen excess similarly but had divergent, and even opposing, effects on other outcomes. Six months posttreatment, the PioFluMet-treated girls had a lower glucose-induced insulinemia, a lower C-reactive protein level, and a thinner intima media than the EE-CA–treated girls, and they were viscerally less adipose, had a higher lean mass, and were more likely to he regular cycles. ConclusionsThe on-treatment and post-treatment effects of PioFluMet compared forably with those of oral contraception in nonobese adolescents with androgen excess. The intervention whereby androgen excess is reduced in adolescence influences the post-treatment phenotype. PioFluMet-like interventions in adolescence may thus hold the potential to prevent part of the androgen-excess phenotype in hood, including adiposity and subfertility.